Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in CIDP to enable immunoglobulin withdrawal
2017-005034-36Phase 3Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Rituximab with Placebo (2 arms). Primary endpoint: Clinical worsening within 6 months after immunoglobulin suspension. Started Nov 2020; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2017-005034-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005034-36.